Format

Send to

Choose Destination
Int J Hematol. 2011 Jul;94(1):11-23. doi: 10.1007/s12185-011-0857-0. Epub 2011 Apr 27.

Polycomb group proteins in hematopoietic stem cell aging and malignancies.

Author information

1
Department of Cell Biology, Section of Stem Cell Biology, University Medical Center Groningen, University of Groningen, A. Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
2
European Research Institute on the Biology of Ageing (ERIBA), Groningen, The Netherlands.
3
Department of Cell Biology, Section of Stem Cell Biology, University Medical Center Groningen, University of Groningen, A. Deusinglaan 1, 9713 AV, Groningen, The Netherlands. G.de.Haan@med.umcg.nl.
4
European Research Institute on the Biology of Ageing (ERIBA), Groningen, The Netherlands. G.de.Haan@med.umcg.nl.

Abstract

Protection of the transcriptional "stemness" network is important to maintain a healthy hematopoietic stem cells (HSCs) compartment during the lifetime of the organism. Recent evidence shows that fundamental changes in the epigenetic status of HSCs might be one of the driving forces behind many age-related HSC changes and might pave the way for HSC malignant transformation and subsequent leukemia development, the incidence of which increases exponentially with age. Polycomb group (PcG) proteins are key epigenetic regulators of HSC cellular fate decisions and are often found to be misregulated in human hematopoietic malignancies. In this review, we speculate that PcG proteins balance HSC aging against the risk of developing cancer, since a disturbance in PcG genes and proteins affects several important cellular processes such as cell fate decisions, senescence, apoptosis, and DNA damage repair.

PMID:
21523335
DOI:
10.1007/s12185-011-0857-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center